Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
INBX · Nasdaq · United States · Biological Products, (No Diagnostic Substances)
In shortInhibrx Biosciences, Inc. is loss-making, burns cash and holds more cash than debt, with revenue growing (+550.0% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -10386.5% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -10773.5% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -197.8% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -98.3% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.93× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 12.58× | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -11.07× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -7.18 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -9986.5% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 3 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 3 | 33/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 2 | 17/100 |
| Revenue growth volatility | 451.8% | 0/100 |
| Operating margin volatility | 89171.2% | 0/100 |
Weight in the score: 20%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 3 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 1.8 | 0.2 | 1.3 |
| Research & development | 192 | 204 | 113 |
| Operating income | (219) | (331) | (135) |
| Interest expense | 32 | 13 | 12 |
| Pre-tax income | (240) | 1,688 | (140) |
| Income tax | 0 | 0 | 0 |
| Net income | (241) | 1,688 | (140) |
| Diluted EPS | −$20.48 | $112.62 | −$9.04 |
| Diluted shares (millions) | 12 | 15 | 15 |
−7.18 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
2/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 13, 2026